Immix Biopharma (NASDAQ: IMMX) grants RSUs and stock options to director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Immix Biopharma director Magda Marquet reported new equity awards in the form of restricted stock units and stock options. On May 22, 2026, she was granted 6,250 restricted stock units under the company’s 2021 Equity Incentive Plan and 12,500 stock options with an exercise price of $8.78 per share.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of Immix Biopharma’s 2027 annual stockholder meeting, subject to continued service. The stock options vest in substantially equal monthly installments over 12 months, or fully on the 2027 annual meeting date if it occurs earlier, also subject to her continued board service.
Following these awards, Marquet directly holds 52,342 shares of common stock and 12,500 stock options, and is associated with 20,000 additional shares held indirectly by Alma Life Sciences, LLC, for which she disclaims beneficial ownership beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Marquet Magda
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Grant/Award | Common Stock | 6,250 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 12,500 shares (Direct, null);
Common Stock — 52,342 shares (Direct, null);
Common Stock — 20,000 shares (Indirect, by ALMA Life Sciences, LLC)
Footnotes (1)
- The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. The Reporting Person is the Co-Founder and Co-Chief Executive Officer of Alma Life Sciences, LLC and may be deemed to beneficially own the securities held by Alma Life Sciences, LLC. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Alma Life Sciences, LLC, except to the extent of her pecuniary interest therein. The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Key Figures
RSU grant size: 6,250 RSUs
Stock options granted: 12,500 options
Option exercise price: $8.78 per share
+3 more
6 metrics
RSU grant size
6,250 RSUs
Granted May 22, 2026 under 2021 Equity Incentive Plan
Stock options granted
12,500 options
Granted May 22, 2026, underlying common stock
Option exercise price
$8.78 per share
Stock option conversion or exercise price
Option expiration
May 22, 2036
Expiration date of stock options
Direct common shares after grant
52,342 shares
Total direct holdings following transactions
Indirect common shares
20,000 shares
Held by Alma Life Sciences, LLC, reported as indirect
Key Terms
restricted stock units, 2021 Equity Incentive Plan, pecuniary interest, stock option, +1 more
5 terms
restricted stock units financial
"The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Equity Incentive Plan financial
"6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of the common stock owned directly by Alma Life Sciences, LLC, except to the extent of her pecuniary interest therein"
stock option financial
"The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did Immix Biopharma (IMMX) director Magda Marquet receive?
Magda Marquet received 6,250 restricted stock units and 12,500 stock options from Immix Biopharma. The RSUs were granted under the 2021 Equity Incentive Plan, and the options carry an exercise price of $8.78 per share, aligning her compensation with shareholder equity performance.
How do the new RSUs granted to Immix Biopharma (IMMX) director Magda Marquet vest?
The 6,250 RSUs vest in full on the earlier of one year after the May 22, 2026 grant date or the 2027 annual stockholder meeting. Vesting is conditioned on Marquet’s continued service with Immix Biopharma through the relevant vesting date, tying compensation to ongoing board involvement.
What are the vesting terms of Magda Marquet’s new Immix Biopharma (IMMX) stock options?
The 12,500 stock options vest in substantially equal monthly installments over the 12 months following May 22, 2026. If the 2027 annual meeting occurs earlier, any remaining unvested options vest at that meeting, provided Marquet remains on Immix Biopharma’s board through each vesting date.
What is the exercise price and expiration date of Magda Marquet’s Immix Biopharma (IMMX) options?
The granted stock options have an exercise price of $8.78 per share and expire on May 22, 2036. This long-dated option term gives Marquet a multi-year window to exercise, linking potential value to Immix Biopharma’s share price over the coming decade.
What is Alma Life Sciences, LLC’s role in Immix Biopharma (IMMX) director Magda Marquet’s holdings?
Alma Life Sciences, LLC holds 20,000 Immix Biopharma shares reported as indirect holdings for Magda Marquet. She is Co-Founder and Co-Chief Executive Officer of Alma Life Sciences and may be deemed to beneficially own these shares, but disclaims ownership except for her pecuniary interest.